AHA 21: SGLT2 is Associated with Reduction in Atrial-Arrythmic Events

Published: 24 Nov 2021

  • Views:

    Views Icon 63
  • Likes:

    Heart Icon 0

In this interview, Dr Illan Goldenberg (University of Rochester Medical Center, Rochester, NY, US) presents the findings of a study aiming to evaluate the effect of SGLT2is on atrial arrhythmia burden in patients with ICDs. Originally revealed at AHA 2021, the results suggest that treatment with SGLT2 inhibitors was associated with a significant reduction in the risk of total atrial arrhythmic events and all-cause mortality.


Discussion points:

Background Study

Design and Patient Population

Key Findings

Take-Home Messages

Next Steps


Recorded remotely from New York, 2021.

Interviewer: Jordan Rance

Videography: Dan Brent